Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions
Public ClinicalTrials.gov record NCT03912428. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Evaluation of a Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Background: Inflammation plays a significant role in various disorders that involve neurodegeneration or autoimmune reaction as one of their mechanisms. PET scans can help detect inflammation. Two new drugs may create better PET images. Objective: \- To see if the drug \[11C\]MC1 can help image inflammation. Eligibility: * People age 18 and older with rheumatoid arthritis or idiopathic inflammatory myopathy (IIM). * Healthy volunteers enrolled in protocol 01-M-0254 or 17-M-0181 are also needed. Design: * Healthy participants will be screened under protocol 01-M-0254 or 17-M-0181. * Participants with arthritis or IIM will have a screening visit. This will include: * Medical history * Physical exam * Blood and urine tests * Possible CT or X-ray: A machine will take pictures of the body. * Healthy participants will have 1 or 2 visits. They may have urine tests. They may take the drug celecoxib by mouth. They will have a PET scan. A small amount of one or both study drugs will be injected through a catheter: A needle will guide a thin plastic tube into an arm vein. Another catheter will draw blood. They will like on a bed that slides into a machine. Their vital signs and heart activity will be measured. * Participants with arthritis will have up to 2 visits after screening. They may take celecoxib and have PET scans. * Participants with IIM will have up to 3 visits after screening. At 1 or 2 visits, they will take celecoxib and have PET scans. They will have 1 visit where they have an MRI: They will lie on a table that slides into a machine. The machine takes pictures of the body.
Study identification
- NCT ID
- NCT03912428
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 31 participants
Conditions and interventions
Interventions
- 11C-MC1 Drug
- Celecoxib Drug
- [11C]ER176 Drug
- Positron Emission Tomography (PET)/computed tomography (CT) Scan Diagnostic Test
Drug · Diagnostic Test
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 13, 2019
- Primary completion
- Jun 13, 2024
- Completion
- Jun 13, 2024
- Last update posted
- Sep 15, 2025
2019 – 2024
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| National Institutes of Health Clinical Center | Bethesda | Maryland | 20892 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03912428, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 15, 2025 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03912428 live on ClinicalTrials.gov.